Federal Register / Vol. 65, No. 97 / Thursday, May 18, 2000 / Notices 31577

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Health Resources and Services

Administration

White House Initiative on Asian

Americans and Pacific Islanders,

President’s Advisory Commission;

Notice of Meeting; Correction

In Federal Register Document 00–

11449 appearing on page 26219 in the

issue for Friday, May 5, 2000, the

following corrections have been made to

the Notice of Meeting for the President’s

Advisory Commission. The room

number for the meeting on May 17, 2000

has been changed from Room 800 of the

Hubert H. Humphrey Building to the

Stonehenge Room of the Hubert H.

Humphrey Building. A time change has

taken place for the meeting on May 19,

2000. The meeting will take place from

9:00 a.m.–1:00 p.m. Those are the only

changes to be noted. All other

information is correct as it appears.

An additional meeting has been

scheduled and will take place on

Thursday, May 18, 2000. This meeting

will be open to the public. The meeting

will be held on May 18, 2000 from 2:00

p.m.–5:00 p.m. in Room 800 of the

Hubert H. Humphrey Building located

at 200 Independence Avenue, SW,

Washington, DC 20201.

Requests to address the Commission

should be made in writing and should

include the name, address, telephone

number and business or professional

affiliation of the interested party.

Individuals or groups addressing similar

issues are encouraged to combine

comments and present through a single

representative. The allocation of time

for remarks may be adjusted to

accommodate the level of expressed

interest. Written requests should be

faxed to (301) 443–0259. Anyone who

has interest in attending any portion of

the meetings or who requires additional

information about the Commission

should contact: Mr. Tyson Nakashima,

Office of the White House Initiative on

Asian Americans and Pacific Islanders,

Parklawn Building, Room 10–42, 5600

Fishers Lane, Rockville, MD 20857,

Telephone (301) 443–2492. Anyone who

requires special assistance, such as sign

language interpretation or other

reasonable accommodations, should

contact Mr. Nakashima no later than

Tuesday, May 16, 2000.

Dated: May 11, 2000.

Jane M. Harrison,

Director, Division of Policy Review and

Coordination.

[FR Doc. 00–12445 Filed 5–17–00; 8:45 am]

BILLING CODE 4160–15–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by writing

to the indicated licensing contact at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

Mutant Aequorea Victoria Fluorescent

Proteins Having Increased Cellular

Fluorescence

George N. Pavlakis, George A.

Gaitanaris, Roland H. Stauber, John N.

Vournakis (NCI)

U.S. Patent 6,027,881 issued 22

February 2000

Licensing Contact: Girish C. Barua; 301/

406–7056 ext. 263; e-mail:

gb18t@nih.gov

The Green Fluorescent Protein (GFP)

from the jellyfish Aequorea victoria is

rapidly becoming an important reporter

molecule for monitoring gene

expression in vivo, in situ and in real

time. GFP can be used to tag proteins,

cellular compartments, or cells, and has

found many uses in the study of

biological processes. Unlike other

bioluminescent reporters, GFP

fluoresces in the absence of any other

proteins, substrates, or cofactors.

Improved signal to noise ratio is

important for several applications using

GFP. We have generated GFP mutants

that increase the fluorescent signal by at

least tenfold over the wild-type GFP in

mammalian cells. These mutants emit

either green or blue light, detectable

when single copy genes are inserted into

the cell.

Method for Refolding Recombinant

Endostatin

Dong Xie, Paul Grulich, John W.

Erickson (NCI)

DHHS Reference No. E–260–99/0 filed

18 Feb 2000

Licensing Contact: Richard Rodriguez;

301/496–7056 ext. 287; e-mail

rr154Z@nih.gov

Endostatin is a naturally occurring

collagen-derived fragment that has been

the subject of intense interest due to its

reported anti-tumor and anti-metastatic

properties. Endostatin’s exact mode of

action is unknown, and a detailed

analysis of this mode of action has been

hampered by the inability to

consistently produce large quantities of

refolded recombinant endostatin. While

endostatin can be recombinantly

produced, the isolated protein is found

in an unfolded state. Thus a need exists

to produce recombinant endostatin in a

biologically active form for continuing

clinical development and studying

specific motifs or structures associated

with endostatin which may be

responsible for its anti-angiogenic/

metastatic properties. The current

invention comprises a method of

renaturing endostatin comprising

contacting unfolded endostatin with an

effective amount of cyclodextrin in an

aqueous environment buffered at a

neutral or acidic ph.

CpG Oligodeoxynucleotides Used To

Improve Human Immune Responses

Dennis Klinman, Daniela Verthelyi,

Kenji Ishii (FDA)

DHHS Reference No. E–078–00/0 filed

14 Jan 2000

Licensing Contact: Peter Soukas; 301–

496–7056, ext. 268; e-mail:

ps193c@nih.gov

This invention concerns immuneactivating oligonucleotides containing

CpG motifs. Although it is known that

certain CpG sequences can induce

responses from human immune system

cells, individual subjects show

considerable heterogeneity in their

response to different CpG sequences.

These different responses make it

difficult to induce a therapeutic

immune response in all members of a

diverse population using a single CpG

sequence, even if such a sequence is

repeated in a CpG oligonucleotide. The

inventors have found that a broad-based

immunomodulatory response scan be

generated in a wide cross-section of

subjects by using a mixture of multiple

different CpG motifs. The mixture of

oligodeoxynucleotides of the present

invention can either be mixtures of

different oligodeoxynucleotides

expressing different CpG motif is or a